ClinicalTrials.gg
Active, not recruitingNCT06778265Updated Jun 11, 2026

An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease

A Phase 1 interventional study of UX-DA001 in Parkinson Disease, Idiopathic, sponsored by Shanghai UniXell Biotechnology Co., Ltd. Active, not recruiting at 1 site in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Shanghai UniXell Biotechnology Co., Ltd · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Planned enrollment
174th of 211
12 · median 47
Started
2025
with 32 others
Phase 1
39 of 279
22 open now
Primary completion
2027-12
later than 103 of 134 live
Registered
194th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 174th largest by planned enrollment of the 211 interventional ones that give a count, is one of 33 that started in 2025, is one of 39 in phase 1, reaches primary completion later than 103 of the 134 other live ones, and was the 194th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

This clinical study is designed to explore the safety and tolerability of UX-DA001. It will also explore if UX-DA001 works to improve motor function in subjects with Parkinson's disease. UX-DA001 manufactured from participant's own cells will differentiate into mature dopaminergic neurons after being transplanted into the brain of the participant.

Read the detailed description

This study is an open-label, multi-center, dose-escalation and dose-expansion exploratory clinical study to evaluate the safety, tolerability, and potential efficacy of UX-DA001 Injection at different dose levels implanted in subjects with idiopathic PD.

Each subject receives only one dose of UX-DA001 for implantation into the putamen bilaterally using stereotactic neurosurgery under general anesthesia. Safety and tolerability of UX-DA001 and its effect on Parkinson's disease symptoms are assessed for 2 years post-treatment.

03

Conditions studied

  • Parkinson Disease, Idiopathic

Browse trials for

Keywords

  • Idiopathic Parkinson´s Disease
  • autologous iPSC derived mDAPs
  • Midbrain Dopaminergic Progenitors
  • Induced pluripotent stem cells
  • mDAPs
  • stem cells
  • iPSC derived product
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subjects or their legally acceptable representative understand and comply with the study procedures, agree to participate in the clinical trial, and sign the ICF;
  2. Aged between 50-75 years old, male or female;
  3. Subjects diagnosed with idiopathic PD, with a medical history of 5-20 years;
  4. Having received standard anti-PD treatment and been given optimal anti-PD treatment under the guidance of the investigator, but the efficacy has significantly declined;
  5. Good response to levodopa medications; the LCT shows that the maximum improvement rate of the UPDRS part III score exceeds 30%;
  6. The modified H\&Y scale of clinical "OFF" period is ≥ Stage 3 and ≤ Stage 4;
  7. Taking a stable dosage of anti-PD medications for at least 4 weeks;
  8. Good physical condition or stable concomitant diseases;
  9. With reliable caregivers who can cooperate to complete the assessment items;
  10. Subjects with good compliance.

Exclusion criteria

Exclusion Criteria:

  1. PD Subjects in whom previous genetic testing has found a GBA gene mutation or PD Subjects whom the investigator considers unsuitable for participation in this clinical study due to other gene mutations;
  2. Subjects with the atypical Parkinson's syndrome or secondary Parkinson's syndrome;
  3. Subjects with , , , treponema pallidum (TP) infection, or other active infections;
  4. Subjects infected with HTLV, EBV or CMV whose infection renders their blood cells unsuitable for cell product preparation;
  5. Subjects with a known hereditary disorder;
  6. Subjects with any history of ;
  7. Subjects with other serious systemic diseases or functional disorders;
  8. Accompanied by other serious central nervous system diseases or serious cognitive and mental disorders;
  9. Subjects who are currently receiving or have previously received cell therapy or other medicine effecting safety and efficacy assessement;
  10. Subjects whose prior head CT/MRI examinations indicate brain injury, or Subjects with imaging abnormalities in the striatum and other brain regions leading to a significant increase in surgical risk, or Subjects who have previously undergone brain surgery;
  11. Subjects with abnormal results in coagulation function, or Subjects who have been using anticoagulants for a long time and cannot discontinue use;
  12. Subjects with a history of severe allergy or reactions, or a known history of hypersensitivity, or a history of intolerance to the cellular drug or its ;
  13. Subjects who have undergone other surgeries within the past six months that the investigator deems may affect this trial, or Subjects who cannot tolerate general anesthesia or stereotactic surgery;
  14. Subjects with to MRI and PET scans;
  15. Subjects with a history of alcoholism or drug abuse;
  16. Women during pregnancy or lactation;
  17. Subjects who have participated in other interventional clinical trials or similar clinical trials within the past 3 months;
  18. Subjects with other conditions that are not suitable for participation in the clinical study as judged by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    UX-DA001

    Biological: UX-DA001

Interventions

  • BiologicalUX-DA001

    UX-DA001 (Human Midbrain Dopaminergic Progenitor Cells) is used for treating patients with iPD via implanting into bilateral putamina under stereotactic neurosurgery. Two dose levels will be planned. Each patient only receives one corresponding dose of UX-DA001.

06

What researchers measure

Primary outcomes

  1. The incidence and and severity of adverse events (AEs) associated with surgery and/or investigational product

    The incidence and and severity of adverse events (AEs) associated with surgery and/or investigational product during the surgical treatment period and the 4-week postoperative observation period. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: within 4 weeks post surgery

  2. The incidence and severity of AEs/serious adverse events (SAEs)

    The incidence and severity of AEs/serious adverse events (SAEs) during the study, including AEs and SAEs during the surgery treatment period, postoperative observation period, and follow-up period. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: From baseline to 2 years post surgery

Secondary outcomes

  1. 18F-FP-CIT uptake using positron emission tomography (PET)

    Changes in 18F-FP-CIT uptake using positron emission tomography (PET) from baseline.

    Time frame: From baseline to 2 years post surgery

  2. The situation of implantation and overgrowth of transplanted cells using cranial MRI

    Volume changes of transplanted cells using cranial magnetic resonance imaging (MRI)

    Time frame: From baseline to 2 years post surgery

  3. Changes in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score, part III, from baseline.

    Minimum score: 0; Maximum score: 132; Higher scores mean a worse outcome.

    Time frame: From baseline to 2 years post surgery

  4. Changes in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score, part II, from baseline.

    Minimum score: 0; Maximum score: 52; Higher scores mean a worse outcome.

    Time frame: From baseline to 2 years post surgery

  5. Changes in modified modified Hoehn-Yahr (H&Y) scale from baseline

    Grade 0\~Grade 5, lower grade means a better outcome

    Time frame: From baseline to 2 years post surgery

  6. Changes in daily levodopa equivalent dose (LED) from baseline.

    Time frame: From baseline to 2 years post surgery

  7. Changes in the scores of non-motor symptom scales (NMSS) from baseline.

    Minimum score: 0; Maximum score: 960; Higher scores mean a worse outcome.

    Time frame: From baseline to 2 years post surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 33 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2024
First posted
Jan 16, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06778265
Lead sponsor
Shanghai UniXell Biotechnology Co., Ltd
Collaborators
Ruijin Hospital
Responsible party
Sponsor
First posted
Jan 16, 2025
Start date
Mar 1, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 11, 2026

Study contacts

Jun Liu, MD, PhD
principal investigator · Ruijin Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion